ANAVEX LIFE SCIENCES CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.55 USD | +1.11% |
|
+19.42% | -51.13% |
Valuation
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 166.4 | 273.9 | 1,359 | 804.4 | 536.8 | 385.1 | - | - |
| Enterprise Value (EV) 1 | 166.4 | 273.9 | 1,359 | 804.4 | 536.8 | 385.1 | 385.1 | 385.1 |
| P/E ratio | -5.85 x | -10.1 x | -33.2 x | -16.6 x | -10.9 x | -8.75 x | -7.11 x | -12 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | 113 x |
| EV / Revenue | - | - | - | - | - | - | - | 113 x |
| EV / EBITDA | - | - | - | -15,776,344 x | -9,627,301 x | - | - | - |
| EV / FCF | - | - | - | -33,186,505 x | -19,319,050 x | - | - | - |
| FCF Yield | - | - | - | -0% | -0% | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 52,651 | 60,191 | 75,727 | 77,943 | 81,951 | 84,642 | - | - |
| Reference price 2 | 3.160 | 4.550 | 17.95 | 10.32 | 6.550 | 4.550 | 4.550 | 4.550 |
| Announcement Date | 12/16/19 | 12/28/20 | 11/24/21 | 11/28/22 | 11/27/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 3.4 |
| EBITDA | - | - | - | -50.99 | -55.76 | - | - | - |
| EBIT 1 | - | -31.09 | -42 | -50.99 | -55.76 | -51.66 | -62.65 | -53.3 |
| Operating Margin | - | - | - | - | - | - | - | -1,567.65% |
| Earnings before Tax (EBT) 1 | - | -26.26 | -37.64 | -47.62 | -47.5 | -43.39 | -56.7 | -44.3 |
| Net income 1 | - | -26.28 | -37.91 | -47.98 | -47.5 | -43.58 | -56.7 | -35.5 |
| Net margin | - | - | - | - | - | - | - | -1,044.12% |
| EPS 2 | -0.5400 | -0.4500 | -0.5400 | -0.6200 | -0.6000 | -0.5200 | -0.6400 | -0.3800 |
| Free Cash Flow | - | - | - | -24.24 | -27.78 | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/16/19 | 12/28/20 | 11/24/21 | 11/28/22 | 11/27/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: September | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.72 | -11.52 | -12.46 | -15.28 | -15.38 | -14.19 | -13.53 | -12.65 | - | -12.52 | -13.2 | -14.6 | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -10.85 | -10.41 | -12.28 | -14.08 | -12.99 | -13.06 | -11.24 | -10.21 | - | -10.44 | -11.4 | -12.95 | - | - | - |
| Net income 1 | -10.88 | -10.44 | -12.37 | -14.29 | -12.97 | -13.11 | -11.28 | -10.15 | - | -10.55 | -11.4 | -12.95 | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1400 | -0.1400 | -0.1600 | -0.1800 | -0.1700 | -0.1700 | -0.1400 | -0.1200 | -0.1100 | -0.1300 | -0.1350 | -0.1500 | -0.1900 | -0.2000 | -0.2300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/9/22 | 5/10/22 | 8/9/22 | 11/28/22 | 2/7/23 | 5/9/23 | 8/8/23 | 11/27/23 | 2/7/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | -24.2 | -27.8 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 12/28/20 | 11/24/21 | 11/28/22 | 11/27/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.55
USD
Average target price
27.5
USD
Spread / Average Target
+504.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.13% | 385M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -2.62% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- AVXL Stock
- Financials Anavex Life Sciences Corp.
